Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | HINT1 | P49773 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24789717 | 0.93 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL30091018 | 0.93 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL24917087 | 0.93 | ADORA1 (0.47) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL24916872 | 0.90 | ADORA1 (0.51) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL24790427 | 0.89 | ADORA1 (0.47) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL24789480 | 0.88 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL25315414 | 0.88 | ADORA1 (0.42) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL25909131 | 0.87 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL24791037 | 0.86 | ADORA1 (0.49) | ADORA1ADORA3ADORA2BNT5EADORA2A | |
| SCHEMBL24916869 | 0.86 | ADORA1 (0.51) | ADORA1ADORA3ADORA2BNT5EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | ADORA1 244/4885ADORA3 291/4885ADORA2B 476/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | ADORA1 244/4885ADORA3 291/4885ADORA2B 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.